Molecular polymorphism of Abeta in Alzheimer's disease. (1/138)

 (+info)

The molecular pathology of schizophrenia--focus on histone and DNA modifications. (2/138)

 (+info)

Multiple sequence variants in hereditary hemorrhagic telangiectasia cases: illustration of complexity in molecular diagnostic interpretation. (3/138)

 (+info)

Competency-based education for the molecular genetic pathology fellow: a report of the association for molecular pathology training and education committee. (4/138)

 (+info)

GUCY2C reverse transcriptase PCR to stage pN0 colorectal cancer patients. (5/138)

 (+info)

Neuropathology of non-Alzheimer degenerative disorders. (6/138)

Neurodegenerative diseases are characterized by selective and progressive loss of specific populations of neurons, which determines the clinical presentation. The same neuronal populations can be affected in a number of different disorders. Given that the clinical presentation reflects the particular population of neurons that are targets of the disease process, it is clear that for any given clinical syndrome, more than one neurodegenerative disease can account for the clinical syndrome. Because of this clinical ambiguity, for the purpose of this brief review neurodegenerative disorders are classified according to the underlying molecular pathology rather than their clinical presentation. The major neurodegenerative diseases can be classified into amyloidoses, tauopathies, alpha-synucleinopathies and TDP-43 proteinopathies.  (+info)

Expression of Forkhead-box protein A1, a marker of luminal A type breast cancer, parallels low Oncotype DX 21-gene recurrence scores. (7/138)

 (+info)

The effect of primer-template mismatches on the detection and quantification of nucleic acids using the 5' nuclease assay. (8/138)

 (+info)